CatalYm to Present Data on Targeting Novel Checkpoint GDF-15 for Immunotherapy of Cancer at the AACR Annual Meeting 2020

Munich/Germany, June 18th, 2020 – CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced that two abstracts identifying a novel immunoregulatory role for Growth-and-Differentiation Factor 15 (GDF-15) and its effective neutralization by CatalYm’s CTL-002 antibody in cancer have been selected for presentation during the American Association for Cancer Research (AACR) Virtual Annual Meeting II on June 22 – 24, 2020.

Tumor-derived GDF-15 suppresses T-lymphocyte recruitment to the tumor microenvironment” [Abstract #5597, Poster #8]

Session: Inflammation, Immunity, and Cancer / Modifiers of the Tumor Microenvironment 2 [PO.IM02.21]

Date and Time: Monday June 22, 2020 9:00 AM to 6:00 PM

Location: Virtual Meeting II: E-Posters []

The abstract describes in vitro and in vivo data, which demonstrate that tumor cells secrete GDF-15 to block T-cell entry into tumor tissue. Neutralizing GDF-15 with CatalYm‘s proprietary antibody (CTL-002) restored the ability of CD8+ T-cells to enter the tumor microenvironment and restored anti-PD1 activity in an anti-PD1 refractory setting.

“Identifying GDF-15 as potential novel immunotherapeutic target linked to immune cell exclusion in tumors and resistance to anti-PD-1 treatment [Abstract #2161, Poster #22]

Session: Adaptive Immunity to Tumors [PO.IM01.01]

Date and Time: Monday June 22, 2020; 9:00 AM – 6:00 PM

Location: Virtual Meeting II: E-Posters []

The abstract reveals that melanoma patients with high GDF-15 levels have significantly shorter survival and are less likely to respond to anti-PD1 therapy. In addition, intratumoral GDF-15 levels in human melanoma correlated inversely with CD3+ and CD8+ T cell infiltration. Consequently, GDF-15 may serve as a predictive biomarker for anti-PD1 response and potentially represents a novel target in the immunotherapy of cancer to improve tumor immune cell infiltration and response to cancer immunotherapy.

Dr. Manfred Rüdiger, CEO of CatalYm, states:

Our data show that GDF-15 is a novel checkpoint factor secreted by tumors. GDF-15 serves as T cell repellent and may cause low or no response to modern immunotherapies. Neutralizing GDF-15 with our CTL-002 antibody is a novel promising approach to increase response rates of cancer immunotherapies and overall survival of cancer patients.

CTL-002 is set to enter clinical development during 2020.

About CatalYm

CatalYm is a biopharmaceutical company developing novel cancer immunotherapies targeting Growth-and-Differentiation Factor 15 (GDF-15). Apart from its established role in cachexia, GDF-15 has been associated with immunosuppression in tissues and tumors[i] and a rapidly growing body of literature supports the concept that GDF-15 is a major T cell repellent. CatalYm aims to neutralize GDF-15 to turn “cold” tumors “hot” and thereby substantially improving the efficacy of established immunotherapy such as anti-PD1/-PD-L1 checkpoint inhibitors. The company’s lead product candidate CTL-002, a neutralizing GDF-15 antibody, is set to enter clinical development in H2 2020.

The Company was founded in 2016 as a spin-off from Wuerzburg University. CatalYm is led by a seasoned senior executive team with substantial I/O drug development as well as deal making experience and backed by international venture capital investors.

[i] Front. Immunol. 11:951. doi: 10.3389/fimmu.2020.00951

About CTL-002

CTL-002 is a humanized, hinge-stabilized IgG4 monoclonal antibody targeting Growth Differentiation Factor-15 (GDF-15), a remote member of the transforming growth factor β superfamily of cytokines, that is associated with poor outcome and reduced overall survival in a multitude of cancer types and has been linked to immunosuppression in the tumor microenvironment.

CatalYm GmbH
Dr. Manfred Rüdiger, CEO
Am Klopferspitz 19
82152 Martinsried, Planegg

WordPress Cookie Notice by Real Cookie Banner